US Stock MarketDetailed Quotes

REGN Regeneron Pharmaceuticals

Watchlist
  • 754.870
  • +1.840+0.24%
Close Nov 27 16:00 ET
  • 754.870
  • 0.0000.00%
Post 20:01 ET
82.95BMarket Cap18.67P/E (TTM)

Regeneron Pharmaceuticals Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
Total revenue
10.65%3.72B
12.32%3.55B
-0.54%3.15B
7.76%13.12B
0.58%3.43B
14.53%3.36B
10.53%3.16B
6.64%3.16B
-24.26%12.17B
-31.05%3.41B
Operating revenue
11.85%3.61B
11.45%3.44B
-0.59%3.03B
6.55%12.58B
-1.97%3.22B
13.06%3.22B
10.39%3.09B
6.10%3.05B
-25.22%11.81B
-32.45%3.29B
Cost of revenue
12.53%491.1M
18.60%480.2M
-5.18%433.8M
16.37%1.82B
-4.37%517M
37.32%436.4M
36.28%404.9M
12.99%457.5M
-35.98%1.56B
-44.98%540.6M
Gross profit
10.36%3.23B
11.39%3.07B
0.24%2.71B
6.49%11.3B
1.51%2.92B
11.76%2.93B
7.54%2.75B
5.64%2.7B
-22.16%10.61B
-27.60%2.87B
Operating expense
16.24%1.99B
13.63%1.97B
14.74%1.95B
25.80%7.07B
12.81%1.91B
22.99%1.72B
38.58%1.74B
33.62%1.7B
21.10%5.62B
32.43%1.7B
Selling and administrative expenses
11.54%714.4M
16.38%758.8M
14.62%689M
24.36%2.63B
11.69%737.7M
21.05%640.5M
36.89%652M
33.58%601.1M
15.95%2.12B
18.03%660.5M
Research and development costs
18.25%1.27B
10.57%1.2B
13.37%1.25B
23.56%4.44B
12.86%1.18B
18.00%1.08B
36.64%1.09B
30.50%1.1B
25.61%3.59B
41.42%1.04B
Other operating expenses
1,700.00%8M
2,533.33%14.6M
3,160.00%15.3M
97.66%-2.1M
92.42%-500K
98.91%-500K
96.55%-600K
97.52%-500K
-97.15%-89.9M
58.23%-6.6M
Operating profit
2.04%1.24B
7.58%1.09B
-24.36%758.5M
-15.23%4.23B
-14.78%1B
-1.04%1.21B
-22.22%1.02B
-22.06%1B
-44.48%4.99B
-56.22%1.18B
Net non-operating interest income expense
49.78%173.6M
65.59%164.6M
88.34%145.4M
319.96%422.9M
145.57%130.4M
319.93%115.9M
558.28%99.4M
1,475.51%77.2M
975.65%100.7M
67.51%53.1M
Non-operating interest income
40.16%187.4M
51.65%179.4M
69.64%161.5M
209.74%495.9M
110.92%148.7M
211.66%133.7M
319.50%118.3M
414.59%95.2M
249.56%160.1M
--70.5M
Non-operating interest expense
-22.47%13.8M
-21.69%14.8M
-10.56%16.1M
22.90%73M
5.17%18.3M
16.34%17.8M
44.27%18.9M
32.35%18M
3.66%59.4M
23.40%17.4M
Other net income (expense)
138.73%83.7M
1,221.21%370M
8.47%-203.2M
-93.64%-456.8M
-84.92%14.3M
-183.60%-216.1M
90.80%-33M
3.65%-222M
-168.88%-235.9M
143.89%94.8M
Gain on sale of security
234.10%134.5M
1,370.23%392.5M
-19.13%-196.2M
-2,510.58%-250.7M
-65.50%45.2M
-139.44%-100.3M
81.12%-30.9M
22.02%-164.7M
-97.31%10.4M
--131M
Special income (charges)
43.80%-56.2M
---23.9M
87.34%-7.1M
27.05%-186.1M
0.00%-30M
---100M
--0
-99.64%-56.1M
-431.46%-255.1M
37.50%-30M
-Less:Other special charges
-43.80%56.2M
--23.9M
-87.34%7.1M
-27.05%186.1M
0.00%30M
--100M
----
99.64%56.1M
431.46%255.1M
--30M
Other non- operating income (expenses)
134.18%5.4M
166.67%1.4M
108.33%100K
-327.27%-20M
85.48%-900K
-476.19%-15.8M
-210.53%-2.1M
-113.48%-1.2M
120.00%8.8M
98.88%-6.2M
Income before tax
34.41%1.49B
50.35%1.63B
-18.33%700.7M
-13.57%4.2B
-13.37%1.15B
-26.43%1.11B
12.43%1.08B
-19.14%858M
-47.90%4.86B
-47.08%1.32B
Income tax
47.96%152.4M
71.00%195.8M
-152.99%-21.3M
-52.79%245.7M
-109.40%-12M
-46.93%103M
3.06%114.5M
-54.11%40.2M
-58.38%520.4M
-53.50%127.6M
Net income
33.02%1.34B
47.90%1.43B
-11.71%722M
-8.87%3.95B
-3.13%1.16B
-23.40%1.01B
13.65%968.4M
-15.99%817.8M
-46.28%4.34B
-46.29%1.2B
Net income continuous Operations
33.02%1.34B
47.90%1.43B
-11.71%722M
-8.87%3.95B
-3.13%1.16B
-23.40%1.01B
13.65%968.4M
-15.99%817.8M
-46.28%4.34B
-46.29%1.2B
Minority interest income
Net income attributable to the parent company
33.02%1.34B
47.90%1.43B
-11.71%722M
-8.87%3.95B
-3.13%1.16B
-23.40%1.01B
13.65%968.4M
-15.99%817.8M
-46.28%4.34B
-46.29%1.2B
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
33.02%1.34B
47.90%1.43B
-11.71%722M
-8.87%3.95B
-3.13%1.16B
-23.40%1.01B
13.65%968.4M
-15.99%817.8M
-46.28%4.34B
-46.29%1.2B
Basic earnings per share
30.80%12.4
46.41%13.25
-12.30%6.7
-8.54%37.05
-2.77%10.88
-22.99%9.48
14.56%9.05
-16.23%7.64
-46.98%40.51
-46.69%11.19
Diluted earnings per share
29.81%11.54
46.00%12.41
-12.55%6.27
-9.03%34.77
-2.95%10.19
-23.76%8.89
13.79%8.5
-16.72%7.17
-46.89%38.22
-46.67%10.5
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022
Total revenue 10.65%3.72B12.32%3.55B-0.54%3.15B7.76%13.12B0.58%3.43B14.53%3.36B10.53%3.16B6.64%3.16B-24.26%12.17B-31.05%3.41B
Operating revenue 11.85%3.61B11.45%3.44B-0.59%3.03B6.55%12.58B-1.97%3.22B13.06%3.22B10.39%3.09B6.10%3.05B-25.22%11.81B-32.45%3.29B
Cost of revenue 12.53%491.1M18.60%480.2M-5.18%433.8M16.37%1.82B-4.37%517M37.32%436.4M36.28%404.9M12.99%457.5M-35.98%1.56B-44.98%540.6M
Gross profit 10.36%3.23B11.39%3.07B0.24%2.71B6.49%11.3B1.51%2.92B11.76%2.93B7.54%2.75B5.64%2.7B-22.16%10.61B-27.60%2.87B
Operating expense 16.24%1.99B13.63%1.97B14.74%1.95B25.80%7.07B12.81%1.91B22.99%1.72B38.58%1.74B33.62%1.7B21.10%5.62B32.43%1.7B
Selling and administrative expenses 11.54%714.4M16.38%758.8M14.62%689M24.36%2.63B11.69%737.7M21.05%640.5M36.89%652M33.58%601.1M15.95%2.12B18.03%660.5M
Research and development costs 18.25%1.27B10.57%1.2B13.37%1.25B23.56%4.44B12.86%1.18B18.00%1.08B36.64%1.09B30.50%1.1B25.61%3.59B41.42%1.04B
Other operating expenses 1,700.00%8M2,533.33%14.6M3,160.00%15.3M97.66%-2.1M92.42%-500K98.91%-500K96.55%-600K97.52%-500K-97.15%-89.9M58.23%-6.6M
Operating profit 2.04%1.24B7.58%1.09B-24.36%758.5M-15.23%4.23B-14.78%1B-1.04%1.21B-22.22%1.02B-22.06%1B-44.48%4.99B-56.22%1.18B
Net non-operating interest income expense 49.78%173.6M65.59%164.6M88.34%145.4M319.96%422.9M145.57%130.4M319.93%115.9M558.28%99.4M1,475.51%77.2M975.65%100.7M67.51%53.1M
Non-operating interest income 40.16%187.4M51.65%179.4M69.64%161.5M209.74%495.9M110.92%148.7M211.66%133.7M319.50%118.3M414.59%95.2M249.56%160.1M--70.5M
Non-operating interest expense -22.47%13.8M-21.69%14.8M-10.56%16.1M22.90%73M5.17%18.3M16.34%17.8M44.27%18.9M32.35%18M3.66%59.4M23.40%17.4M
Other net income (expense) 138.73%83.7M1,221.21%370M8.47%-203.2M-93.64%-456.8M-84.92%14.3M-183.60%-216.1M90.80%-33M3.65%-222M-168.88%-235.9M143.89%94.8M
Gain on sale of security 234.10%134.5M1,370.23%392.5M-19.13%-196.2M-2,510.58%-250.7M-65.50%45.2M-139.44%-100.3M81.12%-30.9M22.02%-164.7M-97.31%10.4M--131M
Special income (charges) 43.80%-56.2M---23.9M87.34%-7.1M27.05%-186.1M0.00%-30M---100M--0-99.64%-56.1M-431.46%-255.1M37.50%-30M
-Less:Other special charges -43.80%56.2M--23.9M-87.34%7.1M-27.05%186.1M0.00%30M--100M----99.64%56.1M431.46%255.1M--30M
Other non- operating income (expenses) 134.18%5.4M166.67%1.4M108.33%100K-327.27%-20M85.48%-900K-476.19%-15.8M-210.53%-2.1M-113.48%-1.2M120.00%8.8M98.88%-6.2M
Income before tax 34.41%1.49B50.35%1.63B-18.33%700.7M-13.57%4.2B-13.37%1.15B-26.43%1.11B12.43%1.08B-19.14%858M-47.90%4.86B-47.08%1.32B
Income tax 47.96%152.4M71.00%195.8M-152.99%-21.3M-52.79%245.7M-109.40%-12M-46.93%103M3.06%114.5M-54.11%40.2M-58.38%520.4M-53.50%127.6M
Net income 33.02%1.34B47.90%1.43B-11.71%722M-8.87%3.95B-3.13%1.16B-23.40%1.01B13.65%968.4M-15.99%817.8M-46.28%4.34B-46.29%1.2B
Net income continuous Operations 33.02%1.34B47.90%1.43B-11.71%722M-8.87%3.95B-3.13%1.16B-23.40%1.01B13.65%968.4M-15.99%817.8M-46.28%4.34B-46.29%1.2B
Minority interest income
Net income attributable to the parent company 33.02%1.34B47.90%1.43B-11.71%722M-8.87%3.95B-3.13%1.16B-23.40%1.01B13.65%968.4M-15.99%817.8M-46.28%4.34B-46.29%1.2B
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders 33.02%1.34B47.90%1.43B-11.71%722M-8.87%3.95B-3.13%1.16B-23.40%1.01B13.65%968.4M-15.99%817.8M-46.28%4.34B-46.29%1.2B
Basic earnings per share 30.80%12.446.41%13.25-12.30%6.7-8.54%37.05-2.77%10.88-22.99%9.4814.56%9.05-16.23%7.64-46.98%40.51-46.69%11.19
Diluted earnings per share 29.81%11.5446.00%12.41-12.55%6.27-9.03%34.77-2.95%10.19-23.76%8.8913.79%8.5-16.72%7.17-46.89%38.22-46.67%10.5
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ------Unqualified Opinion--------Unqualified Opinion--

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data

Investment Theme Infectious Disease
Infectious Disease
Intraday+0.98%